Trial reportLasers in medical science2026
Treatment of hypertrophic scars using fractional CO2 laser alone in comparison with adding botulinium toxin either intalesional injection or assisted drug delivery.
Trial report in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burns result in hypertrophic scarring, causing functional impairment, cosmetic and psychological concerns. Fractional CO₂ laser and botulinum, have shown promise in treatment. To evaluate the effectiveness of fractional laser treatment alone and combined with botulinum toxin A, delivered either through injections or topical application as fractional laser-assisted drug delivery in hypertrophic burn scar. A randomized comparative trial involving 16 patients with post-burn hypertrophic scars. The scar of each patient was divided into 3 sections: (1) fractional CO₂ laser combined with intralesional botulinum toxin type A, (2) fractional CO₂ laser monotherapy, and (3) fractional CO₂ laser with laser-assisted drug delivery of BTXA. Patients received three treatment sessions at monthly intervals, followed by a three-month follow up. Clinical outcomes were evaluated using the Vancouver Scar Scale. Intralesional BTXA demonstrated superior efficacy, achieving the greatest reductions in VSS (- 58.25%). Intralesional BTXA in combination with fractional CO₂ laser represents a highly effective treatment for post-burn hypertrophic scars, offering superior improvements in scar pliability, contour, and patient comfort compared with laser monotherapy or LADD. These findings support intralesional BTXA as the preferred therapeutic approach, while highlighting the potential of combination protocols for optimizing scar outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.